Document is current
Any future updates will be listed below
-
Authors
Springer, Sandra A. https://orcid.org/0000-0002-6318-1000
Nijhawan, Ank E.
Knight, Kevin
Kuo, Irene
Di Paola, Angela
Schlossberg, Esther
Frank, Cynthia A.
Sanchez, Mark
Pankow, Jennifer
Proffitt, Randi P.
Lehman, Wayne
Pulitzer, Zoe
Thompson, Kelly
Violette, Sandra
Harding, Kathleen K.
,
Brooks, Ralph
Heimer, Robert
Schultheis, Alysse
Van der Wyk, Brent
Hansen, Laura
Torres, M. Brynn
Becan, Jenny
Bennett, Ahrein Johnson
Crawley, Rachel
Joe, George
Jones, Justin
Villare, Stephanie
Behrends, Czarina
Jalali, Ali
Muggeo, Jennifer
Acosta, Melissa
DeMoss, Dustin
Persaud, Donna
Johannsen-Love, Jill
Davis, Frank
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05286879 at ClinicalTrials.govDocuments that mention this clinical trial
Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons
https://doi.org/10.1186/s12879-022-07354-x
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (U01DA053039, K02DA032322)
- License Information
-
More Information
Article History
Received: 1 March 2022
Accepted: 5 April 2022
First Online: 15 April 2022
Declarations
:
: A reliance agreement was executed to allow Texas Christian University (TCU) to be the single Institutional Review Board (IRB) of record for all project sites. All project protocols have been reviewed and approved (IRB # 1920-275). Protocol modifications will be communicated to TCU IRB, clinicaltrials.gov (NCT05286879), and participants (when appropriate) by Site Project Coordinators and site PIs. Additional protections include obtainment of a Certificate of Confidentiality and review and approval of the study protocol by the Office of Human Research Protections at the Department of Health and Human Services. This project will be retrospectively registered on clincialtrials.gov. Written informed consent will be obtained from all project participants.
: Not applicable.
: Author Springer has provided scientific consultation to Alkermes Inc and received NIH and VA grant funding. Dr. Springer has received in-kind study drug donations from Alkermes Inc and Indivior Pharmaceutical Company for NIH-funded research. The authors alone are responsible for the content and writing of this paper.
